Zydus Cadila has received the final approval from the USFDA to market Valsartan and Hydrochlorothiazide Tablets USP (US RLD — Diovan HCT Tablets) in the strengths of 80 mg/12.5 mg, 160 mtg/12.5 mg, 160 mg/25 mg, 320 mtg/12.5 mg, and 320 mg/25 mg. The drug is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
The group now has 256 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003—04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.331.5 as compared to the previous close of Rs. 336.35. The total number of shares traded during the day was 62973 in over 886 trades.
The stock hit an intraday high of Rs. 337.7 and intraday low of 327.65. The net turnover during the day was Rs. 20931079.